ALT 0.00% 0.1¢ analytica limited

Standoff, page-5

  1. 388 Posts.
    lightbulb Created with Sketch. 1
    Here is the email I sent and the response received today from Geoff.

    Hi.
    Just a couple of questions from an existing shareholder.
    1. How is the recruitment for the trials going? Have we filled all the spots, was the response/acceptance beter that we expected?
    2. How is the Early Adopter Program in the USA going?
    3. Have the Distributor plans been confirmed?
    4. Are sales and marketing in place for the spring introduction in the USA?
    5. What has been the response from Clinicians?
    6. What sort of volume are you expecting over the next 6 – 12 mths in the USA
    7. Have we finalised the preparation in the UK for PeriCoach introduction in May 2015?
    8. Has the launch been successful?
    9. What are the sales figures for the UK todate
    10. What stage are we at with the European Distributor? Has this been finalized?
    11. What are some of the details around the order fulfillment and logistics agreement in the UK?
    12. How are sales in Aus & NZ going? In-line with expectations? Is there an upward trend in sales?
    13. Is there any momentum in sales that is identifiable at this stage?

    I understand that you are not be able to disclose a great deal of detail around some of these topics but another update on the progress of some of these things as they happen would be greatly appreciated.

    Thank you and Regards

    RESPONSES.

    Good Morning Mr R,

    Thank you for your questions and your continuing support.

    As you anticipated, to answer many of your questions would require me to disclose information not publicly released.  Please don't take my brevity and opacity below as rudeness.  

    I will discuss your questions with the Board who may, at their discretion, address them in upcoming announcements and updates in more detail than I am able to.

    With all that said....

    1. As expected.
    2. As planned.
    3. Ongoing
    4. As planned.
    5. Outstanding feedback from clinicians, but this is not new.
    6. We will not be publishing sales volumes.
    7. As planned.
    8. As expected.
    9. as per 6.
    10. Ongoing
    11. Confidential.
    12. As expected.
    13. As expected.



    Cheers



    Geoff Daly
    Chief Executive Officer
 
watchlist Created with Sketch. Add ALT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.